|Bid||4.8300 x 4000|
|Ask||4.8500 x 2200|
|Day's Range||4.7400 - 4.9300|
|52 Week Range||2.5000 - 5.8000|
|Beta (5Y Monthly)||1.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.38|
ChromaDex Corp. (NASDAQ:CDXC) announced today it has organized a virtual symposium entitled "Nicotinamide Adenine Dinucleotide (NAD+) in Human Health and Disease: The State of the Science on Nutrition Interventions" tomorrow Tuesday, June 2, from 8:30 to 10:00 AM EDT at NUTRITION 2020 LIVE ONLINE, the annual meeting hosted by the American Society for Nutrition (ASN).
In this article we will take a look at whether hedge funds think ChromaDex Corporation (NASDAQ:CDXC) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from […]
ChromaDex Corp. (NASDAQ:CDXC) today announced its participation in a panel discussion titled "What New Dietary Ingredient Master Files Mean for Innovation & Compliance," hosted by the American Conference Institute (ACI) and Council for Responsible Nutrition (CRN). As the global leader in NAD+ science, ChromaDex maintains three New Dietary Ingredient (NDI) notifications from the Food & Drug Administration (FDA) for its proprietary Niagen® (nicotinamide riboside) ingredient and has obtained further regulatory approval in Canada, the European Union, and Australia.
ChromaDex Corp. (NASDAQ:CDXC) today announced Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa and ChromaDex Chief Scientific Advisor, was named the 2020 recipient of the Mary Swartz Rose Senior Investigator Award from the American Society for Nutrition (ASN) and its Foundation. This award, presented by ASN and supported by the Council for Responsible Nutrition (CRN), recognizes an investigator who has contributed outstanding research in the field of bioactive compounds for human health.
Ladies and gentlemen, thank you for standing by and welcome to ChromaDex Corporation's First Quarter 2020 Earnings Conference Call. This afternoon, ChromaDex issued a news release announcing the company's financial results for the first quarter 2020. If you have not reviewed this information both are available within the Investor Relations section of ChromaDex's website at www.chromadex.com.
ChromaDex (CDXC) delivered earnings and revenue surprises of 18.18% and 4.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex Corp. (NASDAQ:CDXC) today announced the results of several new studies, which have uncovered new clinical and preclinical findings for its Niagen® (nicotinamide riboside, or NR) cellular nutrient, paving the way for continued research. Through its industry leading research program, called the ChromaDex External Research Program (CERP), ChromaDex provides its patented nicotinamide riboside (NR, or Niagen) ingredient to research institutions and universities at no cost. ChromaDex continues to support NAD+ research and through CERP has developed a global community of esteemed researchers exploring the potential Niagen and NAD+ can have on human health.
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Mon., May 11, 2020 at 4:30 p.m. ET to discuss its financial results for the first quarter ended Mar. 31, 2020. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
ChromaDex Corp. (NASDAQ:CDXC) announced today the expansion of its partnership with A.S. Watson Group into Europe and launch of its flagship Tru Niagen® cellular health product online and in over 200 Superdrug stores across the United Kingdom. ChromaDex received authorization to sell its patented ingredient in the European Union earlier this year.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
ChromaDex Corp. (NASDAQ:CDXC) announced today the exclusive launch of its new Tru Niagen® Beauty cellular health and beauty daily supplement with Watsons Hong Kong, available online and in all Watsons stores in Hong Kong.
ChromaDex Corp. (NASDAQ:CDXC), a global scientific authority on nicotinamide adenine dinucleotide (NAD) and innovators behind Niagen® (patented nicotinamide riboside) science, announced today the publication of results from preclinical research on cells and animal tissue infected with Coronavirus and a COVID-19 cadaver in the online scientific publishing website bioRxiv.org investigating the effect of viral infection on levels of NAD within the cell. The data showed a COVID-19 assault on the cells causes a greater than three-fold reduction in NAD and triggers the infected cells to specifically seek out nicotinamide riboside (NR) in an attempt to replenish NAD levels in the face of viral infection. While further research is underway, this early preclinical data suggests that increasing cytoplasmic NAD levels through a NAD precursor, such as NR, may support innate immunity to coronaviruses and other viruses.
Tru Niagen received its listing number on the Australian Registry of Therapeutic Goods (ARTG) on January 8, 2020 (AUST L 328365). Tru Niagen is a breakthrough supplement to increase NAD+ (nicotinamide adenine dinucleotide) levels, help maintain general health and well-being, and support energy levels.
ChromaDex Corporation (NASDAQ:CDXC) shares fell 7.0% to US$3.32 in the week since its latest annual results. The...
ChromaDex Corp. (CDXC) seeks to correct statements made by an unaffiliated third-party, Merkel Media Group on behalf of its unnamed client, implying unsupported health claims about Tru Niagen and COVID-19. ChromaDex is a science-based company, focused on cellular health, and appreciates the magnitude of the COVID-19 crisis. ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age.
ChromaDex (CDXC) delivered earnings and revenue surprises of 8.33% and 2.23%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Fourth Quarter 2019 Highlights vs. Fourth Quarter 2018 Strong growth in net sales to $13.1 million, higher gross margins, and significantly improved marketing efficiency.
NEW YORK, NY / ACCESSWIRE / March 10, 2020 / Chromadex Corp. (NASDAQ:CDXC) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 10, 2020 at 4:30 PM Eastern ...
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChromaDex Corp. (CDXC), a global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, announced today the publication of a preclinical study in the journal Aging and Mechanisms of Disease, part of Nature Partner Journals. Conducted by the National Institute on Aging and the National Institute on Deafness and Other Communication Disorders, components of the National Institutes of Health, and the University of Copenhagen, the study demonstrated a reduction of hearing loss from Niagen® supplementation in mice.